natgillin/translations-raw huggingface dataset:
Add-on to sulphonylurea alone or in combination with metformin
Dodatek k sulfonilsečnini, sami ali v kombinaciji z metforminom
Adding a needle
Dodajanje igle
Adding a NeoSpect scan to a CT scan increased the specificity of the scan, making it easier for the doctor to identify a nodule as malignant.
Dodajanje slikanja z uporabo zdravila NeoScan k računalniški tomografiji (CT) je povečalo specifičnost slikanja in zdravniku olajšalo ugotavljanje malignosti vozliča.
Adding Docetaxel Winthrop to other anticancer treatments produced increases in the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived, in all five types of cancer.
Dodajanje zdravila Docetaxel Winthrop drugim zdravilom za zdravljenje raka je pokazalo, da se je pri vseh petih vrstah raka povečalo število bolnikov, pri katerih se je rak odzval na zdravljenje, ter podaljšal čas do poslabšanja bolezni in čas preživetja.
Adding NovoMix 30 to other antidiabetes medicines also resulted in better control of blood glucose than the other medicines taken alone.
Dodajanje zdravila NovoMix 30 k drugim zdravilom proti sladkorni bolezni je privedlo do boljšega uravnavanja ravni glukoze v krvi kot v primeru uporabe drugih zdravil samostojno.
Adding rosiglitazone to treatment with metformin and a sulphonylurea brought about a small but significant extra reduction in HbA1c levels.
Dodajanje rosiglitazona zdravljenju z metforminom in sulfonilsečnino je pripeljalo do majhnega, vendar pomembnega dodatnega znižanja ravni HbA1c.
Adding Taxotere to other anticancer treatments produced increases in the number of patients whose cancer responded to treatment, how long the patients lived without their disease getting worse and how long the patients survived, in all five types of cancer.
Dodajanje zdravila Taxotere drugim zdravilom za zdravljenje raka je pokazalo, da se je pri vseh petih vrstah raka povečalo število bolnikov, pri katerih se je rak odzval na zdravljenje, ter podaljšal čas do poslabšanja bolezni in čas preživetja.
Adding the dispersible tablets
Vstavljanje disperzibilnih tablet
Adding water
Nalivanje vode
Addison’s disease (a disorder of the adrenal glands causing a lack of some hormones)
Addisonovo bolezen (motnjo nadledvične žleze, ki povzroča pomanjkanje nekaterih hormonov);
Addison’s disease is a condition, known as hypoadrenocorticism, where the adrenal glands (located above the kidneys) do not produce enough of two steroid hormones, called cortisol and aldosterone.
Addisonova bolezen je bolezen, znana kot hipoadenokorticizem, pri kateri nadledvične žleze, ki se nahajajo nad ledvicami, ne tvorijo zadostnih količin dveh steroidnih hormonov, kortizola in aldosterona.
Addition of a single dose of sildenafil to Entresto at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of Entresto alone.
Pri bolnikih, ki so imeli hipertenzijo in so dosegli stanje dinamičnega ravnovesja pri odmerjanju zdravila Entresto, je dodatek enkratnega odmerka sildenafila povzročil bistveno večje znižanje krvnega tlaka kot odmerjanje samo zdravila Entresto.
Addition of a single dose of sildenafil to Neparvis at steady state in patients with hypertension was associated with a significantly greater blood pressure reduction compared to administration of Neparvis alone.
Pri bolnikih, ki so imeli hipertenzijo in so dosegli stanje dinamičnega ravnovesja pri odmerjanju zdravila Neparvis, je dodatek enkratnega odmerka sildenafila povzročil bistveno večje znižanje krvnega tlaka kot odmerjanje samo zdravila Neparvis.
Addition of Avastin to standard of care did not demonstrate clinical benefit in clinical trial BO20924, in 71 evaluable children (from age 6 months to less than 18 years old) patients with metastatic Rhabdomyosarcoma and non-Rhabdomyosarcoma Soft Tissue Sarcoma (see section 4.2 for information on paediatric use).
V kliničnem preskušanju BO20924 dodatek zdravila Avastin k standardemu zdravljenju ni pokazal klinične koristi pri 71 ocenjenih otrocih, starih od 6 mesecev do 18 let, z metastatskim rabdomiosarkomom in ostalimi mehkotkivnimi sarkomi (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Addition of other medicinal products for the treatment of Parkinson’s disease
Dodajanje drugih zdravil za zdravljenje Parkinsonove bolezni
Additional ADRs of at least moderate intensity observed in other trials were angioneurotic oedema, erythema multiforme and haemorrhagic stroke, each reported in no more than 0.5% of patients.
Dodatni neželeni učinki najmanj zmerne jakosti, ki so jih opazili v drugih preskušanjih, so bili angionevrotični edem, multiformni eritem in hemoragični možganski inzult - vsakega od teh so prijavili pri največ 0,5% bolnikov.
Additional adverse drug reactions identified associated with the use of the combination therapy (BR-CAP) were hepatitis B infection (< 1%) and myocardial ischaemia (1.3%).
Dodatno ugotovljena neželena učinka, povezana z uporabo kombiniranega zdravljenja (BR-CAP), sta bila okužba z virusom hepatitisa B (< 1%) in ishemija miokarda (1,3%).
Additional adverse events were seen when topotecan was given in combination with cisplatin, however, these events were seen with cisplatin monotherapy and were not attributable to topotecan.
Pri uporabi topotekana v kombinaciji s cisplatinom so opazili dodatne neželene učinke, vendar so le-te opazili že pri monoterapiji s cisplatinom in jih ni bilo mogoče pripisati topotekanu.
Additional adverse reactions and laboratory abnormalities reported with a ≥5% difference (all grades) in patients treated with the ZALTRAP/FOLFIRI regimen versus the placebo/FOLFIRI regimen
Drugi neželeni učinki in laboratorijske nepravilnosti, zabeleženi z ≥ 5 % razliko (vse stopnje) med prejemniki sheme ZALTRAP/FOLFIRI in prejemniki sheme placebo/FOLFIRI
Additional adverse reactions associated with the use of medicinal products containing pravastatin or fenofibrate observed in clinical trials and post- marketing experience that may potentially occur with Pravafenix are listed below.
Dodatni neželeni učinki, povezani z uporabo zdravil, ki vsebujejo pravastatin ali fenofibrat, ki so jih opazili v kliničnih študijah in pri izkušnjah z zdravilom po začetku trženja in do katerih lahko pride pri uporabi zdravila Pravafenix, so našteti spodaj.
Additional adverse reactions characteristic of an allergic response were also reported – including anaphylactic reaction (18 %) and bronchospasm (4 %).
Navedeni so bili tudi dodatni neželeni učinki v obliki alergijskih reakcij, vključno z anafilaktičnimi reakcijami (18 %) in bronhospazmom (4 %).
Additional adverse reactions not listed in Table 2 have been reported in patients who received other doses (either < or > 3 mg/kg) of ipilimumab in clinical trials of melanoma.
Pri bolnikih, ki so ipilimumab v kliničnih preskušanjih pri melanomu prejemali v drugih odmerkih (bodisi manjših bodisi večjih od 3 mg/kg), so poročali še o dodatnih neželenih učinkih, ki v tabeli 2 niso navedeni.
Additional adverse reactions observed in paediatric studies (aged 1to 17 years).
dodatni neželeni učinki, ki so jih opažali v študijah s pediatričnimi bolniki (starimi od 1 leta do 17 let)
Additional adverse reactions related to post-marketing experience with thalidomide and not seen in the pivotal study include: toxic epidermal necrolysis (see section 4.4), intestinal obstruction, hypothyroidism, sexual dysfunction, tumour lysis syndrome (see section 4.4), gastro-intestinal perforations, allergic reactions (hypersensitivity, angioedema/urticaria) (see section 4.4), hearing impaired or deafness, renal failure, myocardial infarction (see section 4.4), worsening of Parkinson’s disease symptoms, severe infections (e.g. fatal sepsis including septic shock) (see section 4.4), convulsions, atrial fibrillation, atrioventricular block (see section 4.4), menstrual disorders including amenorrhea (see section 4.4), pancreatitis, gastrointestinal haemorrhage (see section 4.4), hepatic disorders (see section 4.4), posterior reversible encephalopathy syndrome (PRES), pulmonary hypertension (see section 4.4) and viral infections, including herpes zoster and hepatitis B virus reactivation (see section 4.4).
Dodatni neželeni učinki, povezani z izkušnjami v obdobju trženja pri talidomidu, ki se niso pojavili pri ključni študiji, vključujejo: toksično epidermalno nekrolizo (glejte poglavje 4.4), zaporo črevesa, hipotiroidizem, spolno disfunkcijo, sindrom tumorske lize (glejte poglavje 4.4), perforacije v prebavilih, alergijske reakcije (preobčutljivost, angioedem/urtikarijo) (glejte poglavje 4.4), okvarjen sluh ali gluhost, odpoved ledvic, miokardni infarkt (glejte poglavje 4.4), poslabšanje simptomov Parkinsonove bolezni, hude okužbe (npr. smrtno nevarno sepso vključno s septičnim šokom) (glejte poglavje 4.4), konvulzije, atrijsko fibrilacijo, atrioventrikularni blok (glejte poglavje 4.4), menstrualne motnje vključno z amenorejo (glejte poglavje 4.4), pankreatitis, gastrointestinalno krvavitev (glejte poglavje 4.4), bolezni jeter (glejte poglavje 4.4), sindrom posteriorne reverzibilne encefalopatije (PRES - Posterior reversible encephalophaty syndrome), pljučno hipertenzijo (glejte poglavje 4.4) in virusne okužbe, vključno z reaktivacijo virusa herpes zoster in virusa hepatitisa B (glejte poglavje 4.4).
Additional adverse reactions reported during post-marketing surveillance are listed below.
Drugi neželeni učinki, o katerih so poročali med postmarketinškim nadzorom, so našteti spodaj:
Additional adverse reactions reported with other nicotinic acid medical products
Dodatni neželeni učinki, o katerih so poročali pri drugih zdravilih z nikotinsko kislino
Additional adverse reactions that have been reported with other nicotinic acid medicinal products (with or without a statin) in post-marketing use or in clinical trials include the following:
Dodatni neželeni učinki, o katerih so poročali v obdobju trženja ali v kliničnih preskušanjih z drugimi zdravili z nikotinsko kislino (z ali brez statina) vključujejo:
Additional adverse reactions that have been seen with either of the active substances (bimatoprost or timolol), and may potentially occur also with GANFORT are listed below in Table 2 (bimatoprost) and Table 3 (timolol):
Dodatni neželeni učinki, ki so jih opazili pri posameznih zdravilnih učinkovinah (bimatoprostu ali timololu) in se lahko pojavijo tudi pri zdravilu GANFORT, so navedeni spodaj v preglednici 2 (bimatoprost) in preglednici 3 (timolol):
Additional adverse reactions that have been seen with either of the active substances (bimatoprost or timolol), and may potentially occur also with GANFORT single-dose, are listed below in Table 3 (bimatoprost) and Table 4 (timolol):
Dodatni neželeni učinki, ki so jih opazili pri posameznih zdravilnih učinkovinah (bimatoprostu ali timololu) in se lahko pojavijo tudi pri zdravilu GANFORT (enoodmerna oblika), so navedeni spodaj v preglednici 3 (bimatoprost) in preglednici 4 (timolol):
Additional adverse reactions that have been seen with ophthalmic beta-blockers and may potentially occur also with GANFORT are listed below in Table 3:
Dodatni neželeni učinki, ki so jih opazili pri očesnih antagonistih adrenergičnih receptorjev beta in se lahko pojavijo tudi pri zdravilu GANFORT, so navedeni spodaj, v preglednici 3:
Additional adverse reactions that have been seen with ophthalmic beta-blockers and may potentially occur also with GANFORT single-dose are listed below in Table 4:
Dodatni neželeni učinki, ki so jih opazili pri očesnih antagonistih adrenergičnih receptorjev beta in se lahko pojavijo tudi pri zdravilu GANFORT (enoodmerna oblika), so navedeni v nadaljevanju v preglednici 4:
Additional adverse reactions were observed in adults treated with the aprepitant (125 mg/80 mg) regimen for chemotherapy induced nausea and vomiting (CINV) and at a greater incidence than with standard therapy: abdominal distension, abdominal pain, acne, anaemia, anxiety, AST increased, asthenia, blood alkaline phosphatase increased, blood sodium decreased, candidiasis, cardiovascular disorder, chest discomfort, cognitive disorder, conjunctivitis, cough, decreased appetite, disorientation, dizziness, duodenal ulcer perforation, dysgeusia, dyspepsia, dysuria, eructation, euphoric mood, faeces hard, fatigue, febrile neutropenia, flatulence, gait disturbance, gastroesophageal reflux disease, glucose urine present, hiccups, hot flush, hyperhidrosis, lethargy, malaise, muscle spasms, muscular weakness, nausea*, neutropenic colitis, neutrophil count decreased, oedema, oropharyngeal pain, palpitations, photosensitivity reaction, pollakiuria, polydipsia, postnasal drip, rash pruritic, red blood cells urine positive, seborrhoea, skin lesion, sneezing, somnolence, staphylococcal infection, stomatitis, throat irritation, tinnitus, urine output increased, vomiting*, weight decreased.
Pri odraslih, ki so se zdravili z aprepitantom zaradi navzee in bruhanja zaradi kemoterapije (CINV – chemotherapy induced nausea and vomiting) (režim 125 mg/80 mg), so poročali še o drugih neželenih učinkih, katerih pogostnost je bila večja kot pri standardnem zdravljenju: napihnjen trebuh, bolečine v trebuhu, akne, anemija, anksioznost, zvišanje vrednosti AST, astenija, zvišanje vrednosti alkalne fosfataze v krvi, znižanje vrednosti natrija v krvi, kandidoza, kardiovaskularne motnje, nelagodje v prsnem košu, kognitivne motnje, konjunktivitis, kašelj, zmanjšan apetit, dezorientacija, omotica, perforirajoč duodenalni ulkus, motnje okusa, dispepsija, disurija, spahovanje, evforično razpoloženje, trdo blato, utrujenost, febrilna nevtropenija, flatulenca, motnja hoje, gastroezofagealna refluksna bolezen, prisotnost glukoze v urinu, kolcanje, navali vročine, hiperhidroza, letargija, splošno slabo počutje, mišični spazmi, mišična oslabelost, navzea*, nevtropenični kolitis, zmanjšano število nevtrofilcev, edem, bolečine v ustih in žrelu, palpitacije, fotosenzitivnostna reakcija, polakisurija, polidipsija, zatekanje izcedka iz nosu v žrelo, srbeči izpuščaj, prisotnost rdečih krvnih celic v urinu, seboreja, lezije kože, kihanje, zaspanost, stafilokokne okužbe, stomatitis, draženje žrela, tinitus, povečano izločanje urina, bruhanje*, zmanjšanje telesne mase.
Additional adverse reactions were observed in patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus*, visual acuity reduced, wheezing.
Drugi neželeni učinki, ki so bili pri bolnikih, ki so prejemali aprepitant zaradi preprečevanja pooperacijske navzee in bruhanja (PONV - postoperative nausea and vomiting) pogostejši kot pri bolnikih, ki so prejemali ondansetron, so: bolečina v zgornjem predelu trebuha, nenormalni črevesni zvoki, zaprtje*, disartrija, dispneja, hipestezija, nespečnost, mioza, navzea, senzorične motnje, nelagodje v želodcu, delna zapora pretoka črevesne vsebine*, zmanjšana ostrina vida in piskanje.
Additional adverse reactions4
Dodatni neželeni učinki
Additional analyses suggest that the surgical procedure type did not influence the trends in efficacy endpoints and the efficacy of IONSYS was similar across the range of body mass indices studied (< 25 to > 40 kg/m2 Body Mass Index).
Dodatne analize so pokazale, da vrsta kirurškega postopka ni vplivala na trende opazovanih dogodkov učinkovitosti, in učinkovitost sistema IONSYS je bila podobna v celotnem preiskovanem razponu indeksov telesne mase (od < 25 do ≥ 40 kg/m2 ITM).
Additional biomarkers other than PD-L1 expression status by Immunohistochemistry (IHC) (e.g.
Raziskati je treba dodatne biomarkerje, ki niso PD-L1 po IHC (Immuno Histo Chemistry) statusu izraženosti (npr.
Additional blood glucose controls should be considered in diabetic patients. β2 adrenoreceptor agonists
Pri bolnikih s sladkorno boleznijo je treba razmisliti o dodatnih kontrolnih meritvah glukoze v krvi.
Additional cases per
Dodatni primeri na
Additional cases per 1,000 ET users over 5 years (95%CI)
Dodatni primeri na 1.000 uporabnic ET v obdobju 5 let (95 % IZ)
Additional cases per 1,000 never-users of HRT over a 5 year period*
Dodatni primeri na 1.000 žensk, ki niso nikoli uporabljale HNZ v obdobju 5 let
Additional caution should be exercised in patients who are prone to a disturbance of water or electrolyte balance (e.g. elderly, patients with CV diseases, diabetes, hypertension), and electrolyte control should be considered.
Pri bolnikih, ki so nagnjeni k motnjam ravnovesja vode ali elektrolitov (tj. starostniki, bolniki z boleznimi srca in ožilja, sladkorno boleznijo, hipertenzijo) morate razmisliti o nadzorovanju elektrolitov.
Additional caution should be exercised with any co-medication which has an effect on the haematopoetic system.
Dodatna previdnost je potrebna pri sočasni uporabi katerega koli zdravila, ki vpliva na hematopoetski sistem.
Additional CE marked oral syringes compatible with the reclosable bottle cap adapter can be obtained from a pharmacy.
Dodatne peroralne brizge z oznako CE, ki so združljive z zamaškom z nastavkom za brizgo, so na voljo v lekarni.
additional contraceptive measures
kontracepcijske metode.
Additional data also supports effectiveness of Kalydeco in children aged 2 to 5 years of age with a G551D or S549N mutation.
Dodatni podatki tudi potrjujejo učinkovitost zdravila Kalydeco pri otrocih, starih od dve do pet let, z mutacijo G551D ali S549N.
Additional data from supportive studies showed a similar effect of Ravicti in children from 2 months of age.
Dodatni podatki iz podpornih študij so pokazali podoben učinek zdravila Ravicti pri otrocih, starih dva meseca ali več.
Additional data is required to conclude on the influence of K103N when associated with other NNRTIs mutations.
Za oceno vpliva K103N skupaj z drugimi mutacijami NNRTI so potrebni dodatni podatki.
Additional dose of 150 mg or 2 mg/kg can
oziroma 2 mg/kg
Additional dose of 300 mg or 4 mg/kg can be considered
Mogoče je razmisliti o uporabi dodatnega odmerka 300 mg oziroma 4 mg/kg
Additional dose of 4 mg/kg can be considered
Mogoče je razmisliti o uporabi dodatnega odmerka 4 mg/kg
Additional doses may need to be considered for persons who do not respond or have a sub- optimal response to a course of vaccinations.
Bolniki z zmanjšanim odzivom na cepljenje ali brez bodo morda potrebovali dodatne odmerke.
Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations.
Pri tistih osebah, ki se ne odzivajo ali imajo nepopoln odziv na cepljenje, je treba razmisliti o dodatnih odmerkih.
Additional effects, observed in other studies included: QTc interval prolongation, LVEF reduction and testicular tubular atrophy, increased mesangial cells in kidney, haemorrhage in gastro-intestinal tract and oral mucosa, and hypertrophy of anterior pituitary cells.
Med dodatnimi učinki, opaženimi v drugih študijah, so bili: podaljšanje intervala QTc, zmanjšanje LVEF in atrofija tubulov v modih, zvečanje mezangijskega matriksa v ledvicah, krvavitve iz prebavil in ustne sluznice ter hipertrofija celic v sprednjem delu hipofize.
Additional efficacy data are available from a randomized, open-label, multicenter phase II study [JapicCTI-121850] conducted in Japanese patients with translocation-related sarcoma (TRS), most common being myxoid round-cell liposarcoma (n=24), synovial sarcoma (n=18), mesenchymal chondrosarcoma (n=6), and extraskeletal Ewing sarcoma/PNET, alveolar soft part sarcoma, alveolar rhabdomyosarcoma and clear cell sarcoma (n=5 each).
Iz randomizirane, odprte multicentrične študije 2. faze [JapicCTI-121850], izvedene pri japonskih bolnikih s sarkomom, povezanim s translokacijo (TRS- translocation-related sarcoma), kjer so bili najpogostejši miksoidni okroglocelični sarkom (n = 24), sinovialni sarkom (n = 18) in mezenhimski hondrosarkom (n = 6) ter zunajskeletni Ewingov sarkom/PNET, alveolarni sarkom mehkih tkiv, alveolarni rabdomiosarkom in svetlocelični sarkom (za vsakega n = 5), so na voljo dodatni podatki o učinkovitosti.
Additional efficacy evaluation of Gardasil 9 against HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and
Dodatno ovrednotenje učinkovitosti cepiva Gardasil 9 proti tipom HPV 6, 11, 16, 18, 31, 33, 45,
Additional endpoints of the study included cytogenetic response (in the 10 mg arm major and minor cytogenetic responses were observed in 30.0% and 24.0% of subjects, respectively), assessment of Health Related Quality of Life (HRQoL) and progression to acute myeloid leukaemia.
Med dodatnimi končnimi cilji študije so bili citogenetski odziv (v skupini z 10 mg so opazili večje oziroma manjše citogenetske odzive pri 30,0 % oziroma 24,0 % preskušancev), ocena z zdravjem povezane kvalitete življenja (HRQoL - Health Related Quality of Life) in napredovanje v akutno mieloično levkemijo.
Additional evaluations included duration of response (DOR) and progression-free survival (PFS) by investigator and blinded independent review committee (BIRC) assessment, and overall survival (OS).
Druge ocene so vključevale trajanje odziva (duration of response, DOR), preživetje brez napredovanja bolezni (progression-free survival, PFS) po oceni raziskovalca in odbora BIRC (blinded independent review committee) ter celokupno preživetje (overall survival, OS).
Additional evidence of efficacy is provided by the randomised, double-blind, placebo-controlled, dose finding phase II trial including a nintedanib 150 mg twice daily dose group.
Dodatne dokaze o učinkovitosti so pridobili z randomiziranim, dvojno slepim, s placebom nadzorovanim preskušanjem za ugotavljanje odmerka faze II, ki je vključevalo skupino, ki je prejemala nintedanib po 150 mg dvakrat na dan.
Additional exploratory pCR rates included nodal status (ypT0/isN0 and ypT0N0).
Dodatni eksplorativni deleži pCR vključujejo status bezgavk (ypT0/isN0 in ypT0N0).
Additional findings at clinically relevant exposures included faecal changes; skeletal muscle twitching or tremors; alopecia; swelling, follicular hyperkeratosis, and inflammation in paw pads; and increased LDL and HDL cholesterol.
Med dodatnimi izsledki, ugotovljenimi ob klinično pomembnih izpostavljenostih, so bili fekalne spremembe, trzanje ali tremor skeletnih mišic, alopecija, oteklost, folikularna hiperkeratoza in vnetje blazinic na šapah ter zvišanje holesterola LDL in HDL.
Additional for 15 mg and 20 mg film-coated tablets:
Dodatno za 15 mg in 20 mg filmsko obložene tablete:
Additional infant formula, beverage or food may be given after consumption of the entire mixture.
Po zaužitju celotne količine mešanice lahko otrok še dodatno zaužije začetno formulo za dojenčke, napitek ali hrano.
Additional Information
Dodatni podatki
Additional information about QT prolonging medicinal agents, is provided in Section 4.4. The influence of TRISENOX on the efficacy of other antileukaemic medicinal products is unknown.
Dodatne informacije o učinkovinah, ki podaljšujejo interval Q-T, so v poglavju 4.4. Vpliv zdravila TRISENOX na učinkovitost drugih zdravil za levkemijo ni znan.
Additional information about these potentially inflammatory adverse reactions is provided in “Description of selected adverse reactions” and section 4.4. Data presented in those sections primarily reflect experience from a Phase 3 study, MDX010-20.
Dodatne informacije o teh potencialno vnetnih neželenih učinkih so na voljo v poglavju »Opis izbranih neželenih učinkov« in v poglavju 4.4. Podatki v teh poglavjih se v glavnem nanašajo na izkušnje iz študije 3. faze, MDX010-20.
Additional information for Temomedac 20 mg hard capsules
Dodatna informacija za Temomedac 20 mg trde kapsule
Additional information in special populations:
Dodatne informacije pri posebnih populacijah:
Additional information is shown in the following Table 3
Dodatni podatki so prikazani v spodnji preglednici 3.